Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 2
2014 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
Maher AR, Theodore G. Maher AR, et al. J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. doi: 10.18553/jmcp.2012.18.s5-b.1. J Manag Care Pharm. 2012. PMID: 22784311 Review.
Beginning in 2006, 9 atypical antipsychotic drugs have been approved by the FDA for indications that were previously off-label uses: aripiprazole (as augmentation for major depressive disorder [MDD] and for autism spectrum disorders), asenapine, clozapine, iloperidone, olanzapine …
Beginning in 2006, 9 atypical antipsychotic drugs have been approved by the FDA for indications that were previously off-label uses: aripipr …
Antidepressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study.
Dörks M, Langner I, Dittmann U, Timmer A, Garbe E. Dörks M, et al. Eur Child Adolesc Psychiatry. 2013 Aug;22(8):511-8. doi: 10.1007/s00787-013-0395-9. Epub 2013 Mar 3. Eur Child Adolesc Psychiatry. 2013. PMID: 23455627
In Germany, the use of selective serotonin reuptake inhibitors (SSRIs) and other antidepressants (OADs) is not licensed for the treatment of depressive disorders in children and adolescents except for fluoxetine, which was approved in 2006. Against this background, antidep …
In Germany, the use of selective serotonin reuptake inhibitors (SSRIs) and other antidepressants (OADs) is not licensed for the treatment of …
Pharmacotherapy in depressed children and adolescents.
Taurines R, Gerlach M, Warnke A, Thome J, Wewetzer C. Taurines R, et al. World J Biol Psychiatry. 2011 Sep;12 Suppl 1:11-5. doi: 10.3109/15622975.2011.600295. World J Biol Psychiatry. 2011. PMID: 21905988 Review.
As first-choice medication for the treatment of juvenile depression, the selective serotonin reuptake inhibitor (SSRI) fluoxetine is recommended, due to its efficacy and approval. As second-choice antidepressants the SSRIs sertraline, escitalopram and citalopram might be u …
As first-choice medication for the treatment of juvenile depression, the selective serotonin reuptake inhibitor (SSRI) fluoxetine is …
Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism.
Mouti A, Reddihough D, Marraffa C, Hazell P, Wray J, Lee K, Kohn M. Mouti A, et al. Trials. 2014 Jun 16;15:230. doi: 10.1186/1745-6215-15-230. Trials. 2014. PMID: 24934401 Free PMC article. Clinical Trial.
The relationship between the effectiveness of fluoxetine treatment and serotonin transporter genotype will also be explored. ...Eligible participants will be randomized to either placebo or fluoxetine for a 16-week period. Medication will be titrated over the first …
The relationship between the effectiveness of fluoxetine treatment and serotonin transporter genotype will also be explored. ...Eligi …
[Depressive disorders in childhood and adolescence - an analysis of KinderAGATE 2010].
Stegmann B, Wenzel-Seifert K, Haen E. Stegmann B, et al. Z Kinder Jugendpsychiatr Psychother. 2013 Mar;41(2):109-19. doi: 10.1024/1422-4917/a000218. Z Kinder Jugendpsychiatr Psychother. 2013. PMID: 23425613 German.
In our sample male patients diagnosed with depression (58 % DPat, mean age 13.8 years) were treated more often and earlier than female patients (42 % DPat, mean age 15.3 years). Fluoxetine and mirtazapine were the most frequently prescribed substances. ...Off-label use see …
In our sample male patients diagnosed with depression (58 % DPat, mean age 13.8 years) were treated more often and earlier than female patie …
Feedback